Ionis Pharmaceuticals (IONS) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 35.5% versus a loss of 65.1%. Over five years, TVTX leads with a +61.9% price change compared with -8.5% for IONS. Travere Therapeutics is the larger company by market cap ($4.51 billion vs $4.43 billion), about 1.0 times the size.
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | TVTX |
|---|---|---|
| Share price | $26.58 | $47.00 |
| Market cap | $4.43B | $4.51B |
| 1-day change | -2.35% | -2.69% |
| YTD return | -66.40% | +23.00% |
| 1-year return | -65.07% | +35.49% |
| 5-year return | -8.50% | +61.90% |
| Forward P/E | — | 8.68 |
| EPS (TTM) | $-3.35 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $490.73M |
| Revenue growth (YoY) | +33.83% | +110.45% |
| Net income (latest FY) | $-381.39M | $-25.55M |
| Gross margin | 98.31% | 97.89% |
| Operating margin | -40.45% | -12.80% |
| Net margin | -40.41% | -5.21% |
| 52-week high | $86.74 | $68.73 |
| 52-week low | $26.53 | $22.59 |
| Distance from 52-week high | -69.36% | -31.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +155.19% | +56.23% |
| Average volume | 3.91M | 1.81M |
| Shares outstanding | 166.55M | 95.99M |
| Employees | 1,485 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed IONS by 100.6 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +33.83%).
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
IONS vs TVTX FAQ
Which is bigger, Ionis Pharmaceuticals or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.51B compared with $4.43B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, IONS or TVTX?
TVTX returned +35.49% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.